154 related articles for article (PubMed ID: 3005141)
1. Serum CA 125 in ovarian pathology and its variation in ovarian carcinoma after integrated therapy.
Pansini F; Bellinazzi A; Rainaldi V; Santoiemma M; Lenzi B; Jacobs M; Mollica G; Bagni B
Gynecol Obstet Invest; 1986; 21(1):47-51. PubMed ID: 3005141
[TBL] [Abstract][Full Text] [Related]
2. [Serum level of the tumor marker CA 125 in ovarian pathology].
Bagni B; Pansini FS; Feggi LM; Prandini N; Mollica G
Radiol Med; 1987 Nov; 74(5):448-50. PubMed ID: 3479814
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated antigen CA 125 in patients with ovarian cancer.
Heinonen PK; Tontti K; Koivula T; Pystynen P
Br J Obstet Gynaecol; 1985 May; 92(5):528-31. PubMed ID: 3857939
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
[TBL] [Abstract][Full Text] [Related]
6. CA-125. Use as a tumor marker with mixed mesodermal tumors of the female genital tract.
Peters WA; Bagley CM; Smith MR
Cancer; 1986 Dec; 58(12):2625-7. PubMed ID: 3022909
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of CA-125 in patients with endometriosis: a preliminary report.
Giudice LC; Jacobs A; Pineda J; Bell CE; Lippmann L
Fertil Steril; 1986 Jun; 45(6):876-8. PubMed ID: 3458595
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer.
Vergote IB; Børmer OP; Abeler VM
Am J Obstet Gynecol; 1987 Jul; 157(1):88-92. PubMed ID: 2440307
[TBL] [Abstract][Full Text] [Related]
9. CA 125 in gynecologic practice.
Malkasian GD; Podratz KC; Stanhope CR; Ritts RE; Zurawski VR
Am J Obstet Gynecol; 1986 Sep; 155(3):515-8. PubMed ID: 2428248
[TBL] [Abstract][Full Text] [Related]
10. Malignant pericardial effusion in ovarian carcinoma cured by systemic chemotherapy.
Mäenpää J; Taina E; Erkkola R
Gynecol Oncol; 1988 Jun; 30(2):298-301. PubMed ID: 3371750
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of pre-operative serum CA 125 in ovarian cancer.
Cruickshank DJ; Fullerton WT; Klopper A
Br J Obstet Gynaecol; 1987 Jul; 94(7):692-5. PubMed ID: 2441738
[TBL] [Abstract][Full Text] [Related]
12. [CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries].
Sagan DL; Chebotareva ED; Evtushenko GV
Med Radiol (Mosk); 1989 Jun; 34(6):39-42. PubMed ID: 2739519
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immunity in patients with ovarian carcinoma.
Chen SY; Koffler D; Cohen CJ
Am J Obstet Gynecol; 1973 Feb; 115(4):467-70. PubMed ID: 4346615
[No Abstract] [Full Text] [Related]
14. Prediction of clinical course and recurrence of human ovarian cancer by several serum tumor markers.
Kikuchi Y; Kita T; Iwano I; Kuki E; Oomori K; Kizawa I
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):69-76. PubMed ID: 2926196
[TBL] [Abstract][Full Text] [Related]
15. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
16. An immunologic comparison between serous cystadenocarcinoma of the ovary and other human gynecologic tumors.
Bhattacharya M; Barlow JJ
Am J Obstet Gynecol; 1973 Nov; 117(6):849-53. PubMed ID: 4126800
[No Abstract] [Full Text] [Related]
17. Monitoring the cytotoxic potential of a sequential polychemotherapy (adriamycin/cisplatin-vincristine/cyclophosphamide-high dose methotrexate) in patients with advanced ovarian cancer with the tumor marker CA-125.
Sevelda P; Dittrich C; Salzer H; Pateisky N; Spona J
Cancer Detect Prev; 1986; 9(5-6):521-8. PubMed ID: 3465442
[TBL] [Abstract][Full Text] [Related]
18. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
19. Ovarian tumor-specific antigens.
Knauf S; Urbach GI
Am J Obstet Gynecol; 1974 Aug; 119(7):966-70. PubMed ID: 4135399
[No Abstract] [Full Text] [Related]
20. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]